Probi AB

行业

饲料, 食品配料

主题

益生菌与发酵菌种

角色

研究机构 — “…th. Founded in 1991 at Lund University, Sweden, the company is headquartered in Lund. It is a vertically integ…”

母公司 / 集团

Symrise AG

为何属于生物经济

Probi是一家全球生物制剂解决方案公司，专注于为食品、健康和制药行业研发和生产益生菌及其他生物制剂配料。

发现途径

Kerry Group; [Rubric] Sweden · food-ingredients

尚未被列为已评级方案的供应商。

• 2025 最新状态: Probi AB于2025年被Symrise AG收购,其股票随后从纳斯达克斯德哥尔摩交易所退市。 ↗ ↗ ↗
• 2026-07-01 Probi celebrates 35 years of science and a new chapter with Symrise
  Probi AB is a science-driven biotics company with a 35-year history, known for clinically documented probiotic strains (notably LP299V) and a broad portfolio across digestive, immune, metabolic, women's, oral, sport, and cognitive health. In 2025 it joined the …
• 2026-08-19 Probi partners with Bower to encourage increased recycling among consumers - Inderes
  Probi AB is actively pursuing sustainability by partnering with the Bower app to incentivize consumer recycling of Probi products in Sweden and Norway, aligning with UN Sustainable Development Goal 12 and aiming to reduce carbon footprint and environmental …
• 2026-08-12 Probi and Örebro University to collaborate on research into exploration of novel, needle free vaccines - Inderes
  Probi AB is collaborating with Örebro University and other Swedish partners on a funded research initiative to develop needle-free vaccines delivered via mucous membranes, using probiotic bacteria as carriers to stimulate immunity.
• 2026-09-01 Probi® highlights new evidence on LP299V® and iron absorption
  Probi AB highlights new evidence that their LP299V® probiotic may enhance non-heme iron bioavailability and support iron status as a bioavailability enhancer, not a replacement for dietary iron or supplements. The review emphasizes strain-specific effects, the …
• 2026-02-25 Probi® launches at Matas, Denmark's leading health retailer - Inderes
  Probi AB is expanding its Nordic footprint by launching its probiotic products in Denmark through Matas, leveraging its scientifically documented formulations and extensive clinical backing to reach Danish consumers; the move aligns with its growth since 1991, …
• 2025-01-16 Symrise completes the recommended offer to the shareholders of Probi at 97.4 per cent and extends the acceptance period - Symrise AG
  Symrise has completed its recommended cash offer for Probi AB at SEK 350 per share, reaching 97.4% ownership after additional purchases, and has extended the acceptance period to 29 January 2025 with settlement for the extended period expected around 3 …

股权与投资方 1

合作与交易 1

同类企业

BioGaia AB · Kijimea (SYNformulas GmbH) · THT · Clasado · Zinereo Pharma · SACCO SYSTEM · Bifodan A/S · EXDEN